Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody

Completed · Phase 1

Conditions studied: Melanoma

In brief

This is an open-label, 2-arm study in which patients are randomized to receive either the formulation that is being used in clinical trials or the formulation that will be used when if the drug becomes commercially available. The purpose of this study is to compare the pharmacokinetics of the two formulations.

Key facts

Study ID

NCT00431275

Run by

AstraZeneca

People needed

85

Starts

2006-06-01

Expected to finish

2008-02-01

Last updated by the study team

2012-06-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Stage III or Stage IV melanoma
• No evidence of disease following resection of melanoma lesions
• Recovered from all prior surgical or adjuvant treatment-related toxicities

You may not qualify if…

• History of chronic inflammatory or autoimmune disease
• History of inflammatory bowel disease

Where it is running

• Research Site — Scottsdale, Arizona, United States
• Research Site — Aurora, Colorado, United States
• Research Site — Aventura, Florida, United States
• Research Site — Miami Beach, Florida, United States
• Research Site — Atlanta, Georgia, United States
• Research Site — New York, New York, United States
• Research Site — Philadelphia, Pennsylvania, United States
• Research Site — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.